

## เอกสารอ้างอิง

1. Michael, S.B. and Joseph, L.G. 1985. Drugs used in the treatment of hyperlipoproteinemias. In A.G. Gilman, L.S. Goodman, T.W. Rall, and F. Murad (eds.) ; Goodman and Gilman's The Pharmacological Basis of Therapeutics. 837-838. Philippines : JMC Press., Inc.
2. Oo-Koh, J. 1989. Antihyperlipidaemic agents, The Index of Medical Specialities, 18: 248. Singapore.
3. Budavari, S. and Maryadele, J.O. 1989. Merck Index 11<sup>th</sup> ed., 686 : U.S.A. : Merck & Co, Inc.
4. Todd, P.A. and Ward, A. 1988. Gemfibrozil. A review of its Pharmacodynamics and Pharmacokinetic Properties, and Therapeutic Use in Dyslipidaemia Drugs, 36 : 315-320 : ADIS Press Limited.
5. Augustin, J and Gnasso, A. 1985. Effect of gemfibrozil on lipids, apolipoprotein and post-heparin lipolytic activities in normolipidemic subjects. In Rickers et al. (Eds). Today's therapeutic trends, 23-29 : Communication Media for Education Inc.

6. Weintraub, M.S., Eisenberg, S. and Breslow, T.L.  
1987. Different patterns of postprandial lipoprotein metabolism in normal, type IIa, type III and type IV hyperlipoproteinemia individuals. Journal of Clinical Investigations, 79 : 1110-1119.
  
7. Bremner, W.F., Third J.L.H.C., Clark B., Constorphine C., Lawrie, T.D.V. 1976 CI-719 in hyperlipoproteinemia. Proceeding of the Royal Society of Medicine, 69 (suppl 2) : 83-87.
  
8. Nikkila E.A., Ylikahri R., Huttunen J.K. 1976. Gemfibrozil : effect on serum lipids, lipoproteins, postheparin plasma lipase activities and glucose tolerance in primary hypertriglyceridaemia. Proceeding of the Royal Society of Medicine, 69 (suppl 2) : 58-63.
  
9. Leiss O., von Bergmann K., Gnasso A., Augustin J., Einfluss von 1984. Gemfibrozil auf den biliaren Lipidstoffwechsel in normolipamischen manlichen Probanden. Verhandlungen der Deutschen Gesellschaft für Innere Medizin. 90 : 1169-1176

10. Leiss O., von Bergmann K., Gnasso A., Augustin J. 1985  
Effect of gemfibrozil on biliary lipid  
metabolism in normolipemic subjects Metabolism  
34 : 74-82.
11. Anon 1982. Lopid<sup>(R)</sup> (gemfibrozil) : compendium of  
pharmacological and clinical studies. Warner  
Lambert Company.
12. Okerholm R.A., Keeley F.J., Peterson F.E., Glazco A.J.  
1976. The metabolism of gemfibrozil.  
Proceeding of the Royal Society of Medicine.  
69 (suppl.2) : 11-14.
13. Hamberger C., Barre J., Zini R., Tarclet A., Houin G.,  
et al. 1986. In vitro binding study of  
gemfibrozil to human serum proteins and  
erythrocytes : interactions with other drugs.  
International Journal of Clinical Pharmacology  
Research 6:441-449.
14. Randinitis E.J., Kirkel A.W., Nelson C., Parker T.D.  
1984. Gas chromatographic determination of  
gemfibrozil and its metabolites in plasma  
and urine Journal of Chromatography. 307 :  
210-215.

15. Smith T.C. 1976 Toleration and bioavailability of gemfibrozil in healthy men. Proceeding of the Royal Society of Medicine. 69 (Suppl 2) : 24-27.
16. Manninen V., Malkonen M., Eisalo A. 1982. Gemfibrozil treatment of dyslipidaemias in renal failure with uraemia or in the nephrotic syndrome. Research and Clinical Forums. 4 : 113-118.
17. Frick M.H., Elo O., Haapa K., Heinonen O.P. and Heinsalmi p., et al 1987. Helsinki Heart Study : primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. New England of Medicine. 317 : 1237-1245.
18. Hodges R.M., Marcus E.L. 1982, Safety of gemfibrozil (Lopid) in clinical use. Research and Clinical Forums 4 : 37-42.
19. Kurtz S.M., Fitzgerald J.E., Fisker R.A., Schardein J.L. and Reutner T.H., et al 1976. Toxicological studies on gemfibrozil. Proceeding of the Royal Society of Medicine. 69 : 15-23.
20. Fukada K., Shindo H., Yamashina S. and Mizuhira V. 1978. Fine structural changes in the hepatic

- microbodies of rat treated with hypolipidemic agents, gemfibrozil and clofibrate. Acta histochemical et. Cytochemica 11 : 432-442.
21. Kahonen M.T., Ylikahri R.H. 1979. Effect of clofibrate and gemfibrozil on the activities of mitochondrial carnitine acyltransferases in rat liver. Atherosclerosis 32 : 47-56.
22. Kallai-Sanfacon M.A., Cayen M.N., Dubuc J., Greselin E., and Dvornik D. 1983. Effect of A.Y -25, 712 and other lipid-lowering agents on liver catalase and liver carnitine acyltransferase in rats. Proceeding of the Society of Experimental Biology and Medicine 173 : 367-371.
23. Lalwani N.D., Reddy M.K., Qureshi S.A., Sirtori S.R. and Abiko Y. et al 1983. Evaluation of selected hypolipidemic agents for the induction of peroxisomal enzymes and peroxisomes proliferation in the rat liver. Human Toxicology 2:27-48.
24. Das A.K., Aquilina J.W., Hajra A.K. 1983. The rapid induction of liver glycerophosphate acyltransferase in mice by clofibrate, a hypolipidemic agent. Journal of Biological Chemistry 258 : 3090-3093.

25. de la Iglesia F.A., Farber E. 1981. Hepatocarcinogenesis of hypolipidemic agents. In Brown & Davis (eds.). Organ-directed toxicity chemical indices and mechanisms (IUPAC) 175-182, Oxford : Pergamon Press.
26. de la Iglesia F.A. 1982. Pharmacology and toxicology of gemfibrozil. In Ricci et al (Eds.). Therapeutic selectivity and risk /benefit assessment of hypolipidemic drugs, 53-55 New York : Raven Press
27. de la Iglesia F.A., Farber E. 1982. Hypolipidemics, carcinogenicity and extrapolation of experimental results for human safety assessments. Toxicologic Pathology 10 : 152-174.
28. de la Iglesia F.A., Lewis J.F., Buchanan R.A., Marcus E.L. and McMahon G. 1982. Light and electron microscopy of liver hyperlipoproteinemic patients under long-term gemfibrozil treatment. Atherosclerosis 43 : 19-37.
29. Fitzgerald J.E., Sanyer J.L., Schardein J.L., Lake R.S. and Mc Guire E.J. et al 1981. Carcinogenbioassay and mutagenicity studies

- with the hypolipidemic agent gemfibrozil.  
Journal of the National Cancer Institute 67:  
 1105-1116.
30. Reddy J.K. 1980 a. Hepatic peroxisome proliferative and carcinogenic effects of hypolipidemic drugs. In Fumagalli et al. (Eds.) Drugs affecting lipid metabolism. 301-309: Amsterdam : Elsevier/North Holland Biochemical Press.
31. Committee of Principle Investigators W.H.O. 1980 Cooperative trial on primary prevention of ischaemic heart disease using clofibrate to lower serum cholesterol ; mortality follow-up Lancet 2: 379-384.
32. De Roberts E.D.P. and De Roberts E.M.F. 1987. Mitochondria and oxidative phosphorylation. Cell and Molecular Biology 8<sup>th</sup> ed. 291-324.
33. Green D.E. and Glodberger. R.F. 1966. In Molecular Insights into the Living Process New York : Academic Press
34. ณัฐาศิริ แซ่ยิบ 2535 การยับยั้งหน้าที่ที่เกี่ยวข้องกับพลังงานของไมโทคอนเดรียที่แยกจากตับหนูขาวโดยเอมีโอตาโรน. วิทยานิพนธ์ปริญญาโท มหาวิทยาลัยเทคโนโลยีพระจอมเกล้าธนบุรี ภาควิชาเภสัชวิทยา คณะเภสัชศาสตร์ จุฬาลงกรณ์มหาวิทยาลัย.

35. De Pierre, J.W. and Ernster, L. 1977. Enzyme topology of intracellular membrane Annu. Rev. Biochem., 46:201
36. Mitchell, P. 1977. A commentary on alternative hypotheses of protonic coupling. FEBS Lett. 78 : 1
37. Maria Erecinska and David F. Wilson 1981. Inhibitors of Mitochondrial Functions International Encyclopedia of Pharmacology and Therapeutics Section 107, 101-144 : Pergamon Press.
38. Hogeboom, E.H. 1955. Methods in Enzymology, 1 : 16-19  
New York : Academic Press.
39. Myers, D.K. and Slater, E.C. 1957. The enzyme hydrolysis of adenine triphosphate by liver mitochondria I. Activities at difference pH value Biochem J. 67: 558-572.
40. Sordahl, L.A., et. al. 1971. Methods in Pharmacology  
In A Schwartz. (ed.), 247-286 New York :  
Merdith Corporation.



41. Fowler, B.A., Lucier, G.W. and Hayes, A.W. 1982  
Principle and Methods of Toxicology. In A.W.  
Hays (ed.), 635-658 New York : Raven Press.
42. Chance, E. and Williams, G.R. 1956. The  
respiratory chain and oxidative  
phosphorylation. Advance Enzymology. 17 : 65-  
134.
43. Estabrook, R.W. 1967. Methods in Enzymology,  
10:41 New York : Academic Press.
44. Bertina, R.M. and Slater, E.C. 1975. The effects  
of phosphate and electron transport on  
the carbonyl cyanide n-chlorophenylhydrazone-  
induced ATPase of rat liver mitochondria.  
Biochem. Biophys. Acta. 376 : 492-504.
45. Weinbach, E.C. 1956. Pentachlorophenyl and  
mitochondrial adenosine triphosphate.  
J. Biol. Chem. 221 : 609.
46. Lowry, O.H., Rosenbrough, N.J., Farr, A.L. and  
Randall, R.J. 1951. Protein measurement  
with Folin Phenol reagent. J. Biol. Chem.  
193 : 265-275.

47. Miller, G.L. 1959 Protein determination for large number of samples. Anal. Chem. 31 : 364.
48. Heytler, P.G. 1981. Uncouplers of oxidative phosphorylation. In : Erecinska, M. and Wilson, D.F. (eds.) International Encyclopedia of Pharmacology and Therapeutics. Section 107. 199-210 : Pergamon Press.
49. Heytler, P.G. 1976. Uncouplers of oxidative phosphorylation. In : Cell Biology. Altman, P.L. and Katz, D.D. (eds.) Biological Handbooks, I 208-217.
50. Hanstein, W.G. 1976. Uncoupling of oxidative phosphorylation. Biochem. Biophys Acta. 456: 129-148.
51. Gugler, R. 1978 Clinical pharmacokinetics of hypolipidaemic drugs. Clinical Pharmacokinetics 3 : 425-439.
52. Brown, M.S. and Goldstein, J.L. 1985. Drugs used in the treatment of hyperlipoproteinemia. In Gilman et al. (Eds.) The pharmacological basis of therapeutics, 7<sup>th</sup> ed. 827-845, New York : McMillan Press.

53. Godinot, C., Gautheron, D.C., Galante, Y. and Hatefi, Y. 1981. Labelling of thiols involved in the activity of complex V of the mitochondrial oxidative phosphorylation system. J. Biol. Chem. 256 : 6776-6782.
54. Le-quoc, K. and Le-quoc, D. 1982. Control of the mitochondrial inner membrane permeability by sulfhydryl groups. Arch. Biochem. Biophys. 216 : 631-651.
55. Robillard, G.T. and Konings, W.N. 1982 A hypothesis for the role of dithiol-disulfide interchange in solute transport and energy-transducing process. Eur. J. Biochem 127 : 597-604.
56. Kessler, R.J., Tyson, C.A. and Green, D.E. 1976. Mechanism of Uncoupling in Mitochondria : Uncouplers as Ionophores for Cycling cations and Protons Proc. Natl. Acad. Sci. USA. 73(9) : 3141-3145.

57. Kessler, R.J., Zande, H.V., Tyson, C.A., Blondin, G. A., Fairfield, J., Glasser, P. and Green, D. E. 1977. Uncouplers and the Molecular Mechanism of Uncoupling in Mitochondria. Proc. Natl. Acad. Sci. USA. 74(6) : 2241-2245.
58. Darnell, J., Lodish, H. and Baltimore, D. 1986. Molecular cell biology. 169-171. USA.
59. สุวัฒนา จุฬาวัฒนกุล, 2529. Gemfibrozil, หิตา นิงสานนท์ (บก.) ยาใหม่ในประเทศไทย เล่ม 2 โครงการคลังข้อมูลยา คณะเภสัชศาสตร์ มหาวิทยาลัยมหิดล, 68.
60. AMA Drug Evaluations, 5<sup>th</sup> ed, WB Saunders Company, Philadelphia, 1983, 1241-2.

## ประวัติผู้เขียน

นางสาวกมลวรรณ ประภัสศิริพันธ์ เกิดวันที่ 11 กรกฎาคม พ.ศ. 2509 ที่โรงพยาบาลหญิง (โรงพยาบาลราชวิถีปัจจุบัน) จ. กรุงเทพฯ จบการศึกษา ระดับมัธยมศึกษาตอนปลายจากโรงเรียนเซนต์ฟรังซิสซาเวียร์ คอนแวนต์ และสำเร็จการศึกษาระดับปริญญาตรี เกษศาสตรบัณฑิต (เกียรตินิยมอันดับสอง) จากคณะเกษตรศาสตร์ มหาวิทยาลัยสงขลานครินทร์ อำเภอหาดใหญ่ จังหวัดสงขลา จากนั้นรับราชการใช้ทุนในตำแหน่งเภสัชกร 3 แผนกเภสัชกรรม โรงพยาบาลพระจอมเกล้า อำเภอเมือง จังหวัดเพชรบุรี ได้เป็นระยะเวลา 1 ปี จึงลาออกจากราชการ และสอบเข้าศึกษาต่อในระดับปริญญา เกษศาสตรมหาบัณฑิต ภาควิชาเภสัชวิทยา บัณฑิตวิทยาลัย จุฬาลงกรณ์มหาวิทยาลัย เมื่อปี พ.ศ. 2534

